--- title: "Puma BioTech | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 44.8 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/285620051.md" datetime: "2026-05-07T21:06:06.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285620051.md) - [en](https://longbridge.com/en/news/285620051.md) - [zh-HK](https://longbridge.com/zh-HK/news/285620051.md) --- # Puma BioTech | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 44.8 M Revenue: As of FY2026 Q1, the actual value is USD 44.8 M, beating the estimate of USD 42 M. EPS: As of FY2026 Q1, the actual value is USD -0.07, beating the estimate of USD -0.17. EBIT: As of FY2026 Q1, the actual value is USD -4.1 M. #### Segment Revenue Puma Biotechnology, Inc.’s product revenue, net, was $42.0 million in the first quarter of 2026, a decrease from $43.1 million in the first quarter of 2025 . Royalty revenue for the same period was $2.8 million, down from $2.9 million in the first quarter of 2025 . Total revenue for the first quarter of 2026 amounted to $44.8 million, a decline from $46.0 million in the first quarter of 2025 . #### Operational Metrics Puma Biotechnology, Inc. reported a GAAP net loss of -$3.8 million for the first quarter of 2026, which is a decrease from net income of $3.0 million in the first quarter of 2025 . The non-GAAP adjusted net loss was -$1.9 million for the first quarter of 2026, compared to a non-GAAP adjusted net income of $5.0 million in the first quarter of 2025 . Total operating costs and expenses increased to $48.6 million in the first quarter of 2026 from $42.0 million in the first quarter of 2025 . Cost of sales was $10.4 million in the first quarter of 2026, a slight decrease from $10.6 million in the first quarter of 2025 . Selling, general and administrative expenses rose to $18.4 million in the first quarter of 2026 from $17.6 million in the first quarter of 2025, primarily due to higher employee compensation and marketing costs . Research and development expenses significantly increased to $19.8 million in the first quarter of 2026, up from $13.8 million in the first quarter of 2025, mainly driven by increased alisertib study activity and employee compensation . Total other income was $0.4 million for the first quarter of 2026, an improvement from total other expenses of -$0.7 million in the first quarter of 2025, largely due to a lower debt balance . #### Cash Flow and Liquidity Net cash provided by operating activities for the first quarter of 2026 was $15.4 million, a substantial increase from $3.6 million in the first quarter of 2025 . As of March 31, 2026, Puma Biotechnology, Inc. held cash, cash equivalents, and marketable securities totaling $101.5 million, an increase from $97.5 million at December 31, 2025 . Total debt stood at $11.3 million as of March 31, 2026, reduced from $22.5 million at December 31, 2025 . The company made the final payment on May 4, 2026, reducing its outstanding debt to zero . Working capital was $82.5 million as of March 31, 2026, compared to $81.4 million at December 31, 2025 . #### Outlook / Guidance Puma Biotechnology, Inc. has raised its 2026 revenue and net income guidance due to increased demand for NERLYNX, anticipating FY 2026 to be the second consecutive year of NERLYNX demand increase year-over-year . For the second quarter of 2026, the company projects total revenue between $52 million and $55 million and net income between $2 million and $4 million . The new full-year 2026 guidance forecasts total revenue of $222 million to $229 million and net income of $16 million to $19 million, representing an increase from prior full-year guidance . ### Related Stocks - [PBYI.US](https://longbridge.com/en/quote/PBYI.US.md) ## Related News & Research - [Puma Biotech CFO Maximo F. Nougues disposes of 9,386 shares for $77,560.24](https://longbridge.com/en/news/292125961.md) - [Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | PBYI Stock News](https://longbridge.com/en/news/285442035.md) - [Bollard Group LLC Reduces Position in Aclaris Therapeutics, Inc. $ACRS](https://longbridge.com/en/news/293815783.md) - [Better dividend king to buy right now: AbbVie or Johnson & Johnson?](https://longbridge.com/en/news/293843937.md) - [Top Executive Makes Bold Insider Bet on Greenland Mines Stock](https://longbridge.com/en/news/293691706.md)